Axsome Therapeutics advertising spend, FY2025
Axsome Therapeutics (AXSM) reported $167M of advertising expense for the fiscal year ended Dec 31, 2025. That is 26.2% of revenue of $638M. Up 65.1% from FY2024.
Key facts
- Ad spend is 4.7x its FY2022 level ($35.3M), slower than revenue (13x).
- FY2025 is the highest year on file, going back to FY2022.
- Largest increase +184.1% in FY2023.
- Ad spend has risen 3 years in a row.
- Axsome Therapeutics spends more on advertising than 46% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 5.8x the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 29.3% of selling, general and administrative expense. Research and development spending was 1.1x advertising. The company reported an operating loss of $167M.
| Advertising | $167M | AdvertisingExpense |
|---|---|---|
| Selling and marketing | $440M | ad spend = 37.9% |
| Selling, general and administrative | $571M | ad spend = 29.3% |
| Research and development | $183M | R&D = 1.1x ad spend |
| Operating loss | -$167M | |
| Net loss | -$183M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167M | +65.1% | $638M | 26.2% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2024 | Dec 31, 2024 | $101M | +0.9% | $386M | 26.2% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2023 | Dec 31, 2023 | $100M | +184.1% | $271M | 37.1% | AdvertisingExpense | 10-K Feb 23, 2026 |
| FY2022 | Dec 31, 2022 | $35.3M | n/a | $50M | 70.5% | AdvertisingExpense | 10-K Feb 18, 2025 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Axsome Therapeutics in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 243 | $169M | 4.0% | +4.5% | FY2025 | |
| 244 | Melco Resorts & Entertainment | $168M | 3.3% | +1.7% | FY2025 |
| 245 | Papa John's | $168M | 8.2% | +2.0% | FY2025 |
| 246 | Axsome Therapeutics | $167M | 26.2% | +65.1% | FY2025 |
| 247 | Groupon | $166M | 33.3% | +15.0% | FY2025 |
| 248 | Zillow Group | $165M | 6.4% | -5.7% | FY2025 |
| 249 | Rush Street Interactive | $165M | 14.5% | +3.8% | FY2025 |
Full ranking of 458 companies · Biggest increases #21 · Highest ad-to-revenue #27 · Ads above operating profit #76
Questions
How much does Axsome Therapeutics spend on advertising?
Axsome Therapeutics spent $167M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 23, 2026.
What percentage of revenue does Axsome Therapeutics spend on advertising?
26.2% of revenue in fiscal 2025 ($167M against $638M). The median across the 458 companies tracked is 4.5%.
Is Axsome Therapeutics spending more on advertising?
Yes. Ad spend rose 65.1% in fiscal 2025 from fiscal 2024. It has risen 3 years in a row.
How does Axsome Therapeutics rank by advertising spend?
#246 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Axsome Therapeutics spend more on advertising than on R&D?
No. In fiscal 2025 it spent $183M on research and development and $167M on advertising.
What does Axsome Therapeutics's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 23, 2026
- Accession number
0001193125-26-064267- Company
- Axsome Therapeutics, Inc., CIK 1579428, SIC 2834 (Pharmaceutical Preparations)
- Headquarters
- New York, NY
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Axsome Therapeutics advertising spend, FY2022-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 23, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/axsome-therapeutics/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies